Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Recall Regulations, 32976-32977 [2011-13941]
Download as PDF
32976
Federal Register / Vol. 76, No. 109 / Tuesday, June 7, 2011 / Notices
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than June 22,
2011.
A. Federal Reserve Bank of St. Louis
(Glenda Wilson, Community Affairs
Officer) P.O. Box 442, St. Louis,
Missouri 63166–2034:
1. Thomas R. Garrison, individually,
and in concert with, and as trustee of
the Thomas R. Garrison Trust U/W
Sheridan Garrison, the Thomas R.
Garrison 2005 Retained Annuity Trust,
and the Estate of F. S. Garrison, all of
Fayetteville, Arkansas; to gain control of
Pinnacle Bancshares, Inc., and thereby
indirectly gain control of Pinnacle Bank,
both in Rogers, Arkansas.
Board of Governors of the Federal Reserve
System, June 2, 2011.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2011–13948 Filed 6–6–11; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0425]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Infant Formula
Recall Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
requirements related to the recall of
infant formula.
DATES: Submit either electronic or
written comments on the collection of
information by August 8, 2011.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
emcdonald on DSK2BSOYB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:30 Jun 06, 2011
Jkt 223001
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes Agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal Agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Infant Formula Recall Regulations—21
CFR 107.230, 107.240, 107.250, 107.260,
and 107.280 (OMB Control Number
0910–0188)—Extension
Section 412(e) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act)
(21 U.S.C. 350a(e)) provides that if the
manufacturer of an infant formula has
knowledge that reasonably supports the
conclusion that an infant formula
processed by that manufacturer has left
its control and may not provide the
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
nutrients required in Section 412(i) of
the FD&C Act or is otherwise
adulterated or misbranded, the
manufacturer must promptly notify the
Secretary of Health and Human Services
(the Secretary). If the Secretary
determines that the infant formula
presents a risk to human health, the
manufacturer must immediately take all
actions necessary to recall shipments of
such infant formula from all wholesale
and retail establishments, consistent
with recall regulations and guidelines
issued by the Secretary. Section
412(f)(2) of the FD&C Act states that the
Secretary shall by regulation prescribe
the scope and extent of recalls of infant
formula necessary and appropriate for
the degree of risk to human health
presented by the formula subject to
recall. FDA’s infant formula recall
regulations in part 107 (21 CFR part
107) implement these statutory
provisions.
Section 107.230 requires each
recalling firm to conduct an infant
formula recall with the following
elements: (1) Evaluate the hazard to
human health, (2) devise a written recall
strategy, (3) promptly notify each
affected direct account (customer) about
the recall, and (4) furnish the
appropriate FDA district office with
copies of these documents. If the
recalled formula presents a risk to
human health, the recalling firm must
also request that each establishment that
sells the recalled formula post (at point
of purchase) a notice of the recall and
provide FDA with a copy of the notice.
Section 107.240 requires the recalling
firm to conduct an infant formula recall
with the following elements: (1) Notify
the appropriate FDA district office of
the recall by telephone within 24 hours,
(2) submit a written report to that office
within 14 days, and (3) submit a written
status report at least every 14 days until
the recall is terminated. Before
terminating a recall, the recalling firm is
required to submit a recommendation
for termination of the recall to the
appropriate FDA district office and wait
for written FDA concurrence
(§ 107.250). Where the recall strategy or
implementation is determined to be
deficient, FDA may require the firm to
change the extent of the recall, carry out
additional effectiveness checks, and
issue additional notifications
(§ 107.260). In addition, to facilitate
location of the product being recalled,
the recalling firm is required to
maintain distribution records for at least
1 year after the expiration of the shelf
life of the infant formula (§ 107.280).
The reporting and recordkeeping
requirements described previously are
designed to enable FDA to monitor the
E:\FR\FM\07JNN1.SGM
07JNN1
32977
Federal Register / Vol. 76, No. 109 / Tuesday, June 7, 2011 / Notices
effectiveness of infant formula recalls in
order to protect babies from infant
formula that may be unsafe because of
contamination or nutritional inadequacy
or otherwise adulterated or misbranded.
FDA uses the information collected
under these regulations to help ensure
that such products are quickly and
efficiently removed from the market.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
107.230
107.240
107.250
107.260
No. of
responses
per
respondent
No. of
respondents
21 CFR Section 2
Average
burden per
response
(in hours)
Total annual
responses
Total hours
................................................................................
................................................................................
................................................................................
................................................................................
2
2
2
1
1
1
1
1
2
2
2
1
4,500
1,482
120
650
9,000
2,964
240
650
Total ..............................................................................
........................
........................
........................
........................
12,854
1
There are no capital costs or operating and maintenance costs associated with this collection of information.
No burden has been estimated for the recordkeeping requirement in § 107.280 because these records are maintained as a usual and customary part of normal business activities. Manufacturers keep infant formula distribution records for the prescribed period as a matter of routine
business practice.
emcdonald on DSK2BSOYB1PROD with NOTICES
2
The reporting burden estimate is
based on Agency records, which show
that there are five manufacturers of
infant formula and that there have been,
on average, two infant formula recalls
per year for the past 3 years. Based on
this information, we estimate that there
will be, on average, approximately two
infant formula recalls per year over the
next 3 years.
Thus, FDA estimates that two
respondents will conduct recalls
annually pursuant to §§ 107.230,
107.240, and 107.250. The estimated
number of respondents for § 107.260 is
minimal because this section is seldom
used by FDA; therefore, the Agency
estimates that there will be one or fewer
respondents annually for § 107.260. The
estimated number of hours per response
is an average based on the Agency’s
experience and information from firms
that have conducted recalls. We
estimate that two respondents will
conduct infant formula recalls under
§ 107.230 and that it will take a
respondent 4,500 hours to comply with
the requirements of that section, for a
total of 9,000 hours. We estimate that
two respondents will conduct infant
formula recalls under § 107.240 and that
it will take a respondent 1,482 hours to
comply with the requirements of that
section, for a total of 2,964 hours. We
estimate that two respondents will
submit recommendations for
termination of infant formula recalls
under § 107.250 and that it will take a
respondent 120 hours to comply with
the requirements of that section, for a
total of 240 hours. Finally, we estimate
that one respondent will need to carry
out additional effectiveness checks and
issue additional notifications under
§ 107.260, for a total of 650 hours.
VerDate Mar<15>2010
17:30 Jun 06, 2011
Jkt 223001
Under 5 CFR 1320.3(b)(2), the time,
effort, and financial resources necessary
to comply with a collection of
information are excluded from the
burden estimate if the reporting,
recordkeeping, or disclosure activities
needed to comply are usual and
customary because they would occur in
the normal course of activities. No
burden has been estimated for the
recordkeeping requirement in § 107.280
because these records are maintained as
a usual and customary part of normal
business activities. Manufacturers keep
infant formula distribution records for
the prescribed period as a matter of
routine business practice.
Dated: June 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–13941 Filed 6–6–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel, Aging and
Economics.
Date: June 24, 2011.
Time: 10 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Rebecca J. Ferrell, PhD,
Scientific Review Officer, National Institute
on Aging, Gateway Building Rm. 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20892,
301–402–7703, ferrellrj@mail.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel, NonCommunicable Diseases.
Date: June 29, 2011.
Time: 12 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C218, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Alfonso R. Latoni, PhD,
Deputy Chief and Scientific Review Officer,
Scientific Review Branch, National Institute
on Aging, 7201 Wisconsin Avenue, Suite
2C218, Bethesda, MD 20892, 301–402–7702,
Alfonso.Latoni@nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel, Statistical
Methods in Aging Research.
Date: July 18, 2011.
Time: 10 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Rebecca J. Ferrell, PhD,
Scientific Review Officer, National Institute
on Aging, Gateway Building Rm. 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20892,
301–402–7703, ferrellrj@mail.nih.gov.
E:\FR\FM\07JNN1.SGM
07JNN1
Agencies
[Federal Register Volume 76, Number 109 (Tuesday, June 7, 2011)]
[Notices]
[Pages 32976-32977]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-13941]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0425]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Infant Formula Recall Regulations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on requirements related to the
recall of infant formula.
DATES: Submit either electronic or written comments on the collection
of information by August 8, 2011.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Infant Formula Recall Regulations--21 CFR 107.230, 107.240, 107.250,
107.260, and 107.280 (OMB Control Number 0910-0188)--Extension
Section 412(e) of the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 350a(e)) provides that if the manufacturer of an
infant formula has knowledge that reasonably supports the conclusion
that an infant formula processed by that manufacturer has left its
control and may not provide the nutrients required in Section 412(i) of
the FD&C Act or is otherwise adulterated or misbranded, the
manufacturer must promptly notify the Secretary of Health and Human
Services (the Secretary). If the Secretary determines that the infant
formula presents a risk to human health, the manufacturer must
immediately take all actions necessary to recall shipments of such
infant formula from all wholesale and retail establishments, consistent
with recall regulations and guidelines issued by the Secretary. Section
412(f)(2) of the FD&C Act states that the Secretary shall by regulation
prescribe the scope and extent of recalls of infant formula necessary
and appropriate for the degree of risk to human health presented by the
formula subject to recall. FDA's infant formula recall regulations in
part 107 (21 CFR part 107) implement these statutory provisions.
Section 107.230 requires each recalling firm to conduct an infant
formula recall with the following elements: (1) Evaluate the hazard to
human health, (2) devise a written recall strategy, (3) promptly notify
each affected direct account (customer) about the recall, and (4)
furnish the appropriate FDA district office with copies of these
documents. If the recalled formula presents a risk to human health, the
recalling firm must also request that each establishment that sells the
recalled formula post (at point of purchase) a notice of the recall and
provide FDA with a copy of the notice. Section 107.240 requires the
recalling firm to conduct an infant formula recall with the following
elements: (1) Notify the appropriate FDA district office of the recall
by telephone within 24 hours, (2) submit a written report to that
office within 14 days, and (3) submit a written status report at least
every 14 days until the recall is terminated. Before terminating a
recall, the recalling firm is required to submit a recommendation for
termination of the recall to the appropriate FDA district office and
wait for written FDA concurrence (Sec. 107.250). Where the recall
strategy or implementation is determined to be deficient, FDA may
require the firm to change the extent of the recall, carry out
additional effectiveness checks, and issue additional notifications
(Sec. 107.260). In addition, to facilitate location of the product
being recalled, the recalling firm is required to maintain distribution
records for at least 1 year after the expiration of the shelf life of
the infant formula (Sec. 107.280).
The reporting and recordkeeping requirements described previously
are designed to enable FDA to monitor the
[[Page 32977]]
effectiveness of infant formula recalls in order to protect babies from
infant formula that may be unsafe because of contamination or
nutritional inadequacy or otherwise adulterated or misbranded. FDA uses
the information collected under these regulations to help ensure that
such products are quickly and efficiently removed from the market.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
No. of No. of Total annual burden per
21 CFR Section \2\ respondents responses per responses response (in Total hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
107.230......................... 2 1 2 4,500 9,000
107.240......................... 2 1 2 1,482 2,964
107.250......................... 2 1 2 120 240
107.260......................... 1 1 1 650 650
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 12,854
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ No burden has been estimated for the recordkeeping requirement in Sec. 107.280 because these records are
maintained as a usual and customary part of normal business activities. Manufacturers keep infant formula
distribution records for the prescribed period as a matter of routine business practice.
The reporting burden estimate is based on Agency records, which
show that there are five manufacturers of infant formula and that there
have been, on average, two infant formula recalls per year for the past
3 years. Based on this information, we estimate that there will be, on
average, approximately two infant formula recalls per year over the
next 3 years.
Thus, FDA estimates that two respondents will conduct recalls
annually pursuant to Sec. Sec. 107.230, 107.240, and 107.250. The
estimated number of respondents for Sec. 107.260 is minimal because
this section is seldom used by FDA; therefore, the Agency estimates
that there will be one or fewer respondents annually for Sec. 107.260.
The estimated number of hours per response is an average based on the
Agency's experience and information from firms that have conducted
recalls. We estimate that two respondents will conduct infant formula
recalls under Sec. 107.230 and that it will take a respondent 4,500
hours to comply with the requirements of that section, for a total of
9,000 hours. We estimate that two respondents will conduct infant
formula recalls under Sec. 107.240 and that it will take a respondent
1,482 hours to comply with the requirements of that section, for a
total of 2,964 hours. We estimate that two respondents will submit
recommendations for termination of infant formula recalls under Sec.
107.250 and that it will take a respondent 120 hours to comply with the
requirements of that section, for a total of 240 hours. Finally, we
estimate that one respondent will need to carry out additional
effectiveness checks and issue additional notifications under Sec.
107.260, for a total of 650 hours.
Under 5 CFR 1320.3(b)(2), the time, effort, and financial resources
necessary to comply with a collection of information are excluded from
the burden estimate if the reporting, recordkeeping, or disclosure
activities needed to comply are usual and customary because they would
occur in the normal course of activities. No burden has been estimated
for the recordkeeping requirement in Sec. 107.280 because these
records are maintained as a usual and customary part of normal business
activities. Manufacturers keep infant formula distribution records for
the prescribed period as a matter of routine business practice.
Dated: June 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-13941 Filed 6-6-11; 8:45 am]
BILLING CODE 4160-01-P